Champions OncologyCSBR -4.71%64 Return-on-Tangible-Equity is -28.68% as of Jan. 2026. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.64 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,199 Biotechnology companies, Champions Oncology ranks worse than 58.63% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Champions Oncology's annualized net income for the quarter that ended in Jan. 2026 was $-1.12 Mil. Champions Oncology's average shareholder tangible equity for the quarter that ended in Jan. 2026 was $3.89 Mil. Therefore, Champions Oncology's annualized Return-on-Tangible-Equity for the quarter that ended in Jan. 2026 was -28.68%.
The historical rank and industry rank for Champions Oncology's Return-on-Tangible-Equity or its related term are showing as below:
CSBR'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -705.38 Med: -30 Max: 784.15
Current: -58.41
During the past 13 years, Champions Oncology's highest Return-on-Tangible-Equity was 784.15%. The lowest was -705.38%. And the median was -30.00%.
CSBR's Return-on-Tangible-Equity is ranked worse than 58.63% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs CSBR: -58.41
Champions Oncology (NAS:CSBR) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Champions Oncology Return-on-Tangible-Equity Related Terms
Champions Oncology Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Champions Oncology's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Champions Oncology Return-on-Tangible-Equity Chart
CSBR vs SEER, RLYB, FBIO: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Champions Oncology's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Champions Oncology Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Champions Oncology's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Champions Oncology's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jan. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -28.68% mean?
Champions Oncology (CSBR) has a Return-on-Tangible-Equity of -28.68% as of Jan. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Champions Oncology and its competitors. According to the industry distribution chart, Champions Oncology ranks #703 out of 1199 companies in the Biotechnology industry, placing it in the top 58.6%.
Is Champions Oncology's Return-on-Tangible-Equity too high?
Champions Oncology's current Return-on-Tangible-Equity is -28.68%. Based on the distribution chart, Champions Oncology ranks #703 out of 1199 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Return-on-Tangible-Equity compare to SEER and RLYB?
According to the Biotechnology industry distribution chart, Champions Oncology ranks #703 out of 1199 companies for Return-on-Tangible-Equity. This places Champions Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Champions Oncology and its competitors. Champions Oncology's current Return-on-Tangible-Equity is -28.68%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.64, compared to a current price of $5.76 — trading 13.3% below its estimated fair value. The current Return-on-Tangible-Equity is -28.68%. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Return-on-Tangible-Equity is -28.68% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Champions Oncology (CSBR) Overvalued in 2026?
Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued.
The current stock price of $5.76 is trading 13.3% below its estimated GF Value™ of $6.64.
GuruFocus considers Champions Oncology to be Modestly Undervalued.
Key valuation signals for CSBR:
Return-on-Tangible-Equity: -28.68%
GF Value™: $6.64 vs. price of $5.76 (13.3% below fair value)
No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score
Get the complete analysis for CSBR
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSBR has been successfully added to your 
